All existing BEVA members will have their membership automatically extended until 30 June 2020. The association is also inviting vets and vet nurses who are not already BEVA members to join as online members free of charge until 30 June 2020.
BEVA President Tim Mair said: “In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD to help them through these dark times.”
BEVA membership includes:
The association is also looking at other ways to support the profession, which has included making all BEVA Congress 2019 webinars available to members via the BEVA online learning platform.
To sign up from Monday 30 March 2020 visit: https://www.beva.org.uk/Join-BEVA
B&W Equine Group has opened a brand new, state-of-the-art equine clinic at Breadstone in Gloucestershire.
The new facility opened on 1 October 2011. It cost over £2.2 million and is, according to the company, one Europe’s most advanced diagnostic and surgical centres.
B&W Equine Group was created in 2008, following a merger between Willesley Equine Clinic and Bushy Equine Vets. The 23 vet practice has four local equine clinics in Breadstone, Cardiff, Failand and Willesley.
The new clinic, located on a four acre site at Breadstone, close to the M4 and M5 intersections, provides state-of-the-art diagnostics and advanced laboratory facilities. It houses the only equine MRI scanner in Wales and the South West, as well as a CT scanner and scintigraphy unit. Orthopaedic and colic theatres, adult and neonatal intensive care suites and separate isolation units have all been custom-designed and are supported by five examination rooms and two knock down boxes.
Clinical and referral services are led by RCVS and European Recognised Specialists in surgery, orthopaedics, diagnostic imaging and internal medicine and include gynaecological management of breeding mares and pre-season disease screening. The on-site laboratory is one of only 30 in the UK to be certified by the HBLB to test for CEM and EVA.
Ian Camm, BVSc CertEP MRCVS, Group Director, said: “We are all extremely excited about the new clinic but our day-to-day first opinion work remains a top priority. For all our local clients it’s very much a case of business as usual but the fact that we have invested in the latest portable equipment, including video endoscopes, digital radiography and ultrasound scanners, means we can undertake more specialist work at client’s yards, as and when needed.”
For further information, visit www.bwequinevets.co.uk.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
A research project funded by equine charity The Horse Trust has found that lameness is the most common reason for euthanasing a geriatric horse.
According to the charity, this research is the first in the UK to provide data on the causes of death in geriatric horses. Although post-mortem studies have provided some data regarding causes of death, "old age" was previously reported as a common reason for the euthanasia of adult horses.
The research was carried out by Joanne Ireland at the University of Liverpool and led by Dr Gina Pinchbeck. Ireland surveyed horse owners living in the North-West and Midlands areas of England and North Wales who have a horse aged 15 years or older. 918 owners of geriatric horses were followed in a cohort study and 118 mortalities were reported during the 18 month follow-up period, of which 111 were euthanased.
The researchers found that 24% of horses were euthanased due to lameness; an additional 12% were euthanased due to laminitis - a common cause of lameness. After lameness, colic was the next most common cause of euthanasia, with 21% of owners citing this as the main reason.
In an earlier stage of the project, the researchers had found that half the geriatric horses surveyed suffered from lameness, but only 24% of owners reported the problem.
Dr Pinchbeck said: "Although lameness is common in older horses, this is the first study to quantify its contribution to their mortality.
"Owners are often missing the early signs of lameness in their horse, which means the condition isn't being managed and may deteriorate faster."
Dr Pinchbeck said it would be useful to carry out further research into lameness in geriatric horses to find out the main causes of lameness and how these may be prevented or treated.
The research team also found that half of the horses euthanased were suffering from concurrent health problems and these influenced the owner's decision to euthanase in 43% of cases. The most frequently reported additional health problems were musculoskeletal problems, such as arthritis.
The mortality rate among the horses surveyed was 11 per 100 horse-years at risk, meaning that if 100 geriatric horses were followed for a year, an average of 11 would die. The mortality rate for horses over 30 years of age was over five times the rate than in horses aged 15 - 19 years.
Jeanette Allen, Chief Executive of The Horse Trust, said the data provided by this research is likely to provide useful information for both horse owners and vets to enable them to improve the welfare of older horses. She said: "As there are a significant number of geriatric horses in the UK, it is vital that we understand more about the health problems that affect them. We hope that more owners of older horses will give their horse an annual health-check to enable the horse to have a longer, healthier life."
The research was published in the September 2011 issue of Preventive Veterinary Medicine.
This year's National Equine Health Survey, conducted by the Blue Cross and supported by Zoetis, has revealed that 20% of owners who claimed to have treated for encysted small redworm (ESRW) used a wormer that was not indicated to treat the parasite.
3,669 horse owners took part in the survey, which was conducted in May 2014. It contained 25 questions on general horse health, care and management and was validated by Professor Josh Slater at the Royal Veterinary College.
Zoetis says the findings suggest that horses are being left at serious risk (untreated, encysted small redworm may develop and emerge en masse from the gut wall, causing diarrhoea and colic with a mortality rate of up to 50%1).
The company is now running an encysted small redworm awareness campaign at www.esrw.co.uk, where owners can test their knowledge before discussing the best treatment options with their vet.
References
1. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242
Three bursaries are available - two in ruminant and one in companion animal research, each worth up to £4,000.
Annabelle Mohring, Veterinary Advisor at MSD Animal Health said: "We appreciate that the last 18 months have been challenging for many veterinary surgeons and adding new research to this may not be considered a priority. But with the pace of change rapidly increasing, improving business skills and scientific knowledge will become more important than ever for the profession.
"Research forms the foundation of the industry and being awarded a bursary has proved to be a career-changing experience for some participants. We're now welcoming applications as part of our investment in the veterinary community."
Each project should be completed within one to two years and the veterinary surgeon proposals will be judged by objective third party university academics to ensure independent assessment.
The deadline for the MSD Animal Health Veterinary Surgeon Research Bursaries is 30th November 2021.
For further information, visit: www.msdahresearchbursary.co.uk.
Photo: Hattie Barnes who was awarded the 2020 Veterinary Surgeon Bursary in the companion animal sector. She was awarded £4,000 for her analytical, cadaver-based study to investigate different draping protocols in elective orthopaedic surgery. Hattie is currently undertaking a 3-year residency in Equine Surgery at the University of Liverpool.
Last year BEVA received a national Antibiotic Guardian award from Public Health England in recognition of its work to promote responsible use of antibiotics. It was the only organisation from the veterinary profession to be shortlisted. BEVA launched its Protect ME antimicrobial campaign in 2012 to coincide with European Antimicrobial Awareness day. The Association has launched additional resources each year to facilitate compliance and educate the public about the importance of antimicrobial awareness.
This year, to recognise World Antibiotic Awareness Week (16th to 22nd November, 2016) and European Antibiotic Awareness Day (18th November), BEVA is encouraging members to document their efforts to reduce the use of critically important antibiotics.
To enter for the award, veterinary surgeons need to share practice sales data (in mls) of chosen antibiotics. Practices that document a reduction in antibiotic sales of these drugs will be presented with a BEVA Antibiotic Champion Award to endorse their commitment to responsible use of antibiotics and to help promote public awareness of the campaign. Members are also encouraged to sign up to be antibiotic guardians at www.antibioticguardian.com
Gayle Hallowell, Co-Chair of the BEVA Health and Medicines Committee said: "We are extremely proud of the equine veterinary profession’s commitment to the responsible use of antibiotics. We hope the introduction of our Champion Award will inject new vigour into efforts to continue to reduce the use of our precariously limited antibiotic resources."
To apply for BEVA Antibiotic Champion Award status visit http://www.beva.org.uk/Antibiotic-Champion-Award The BEVA Protect ME toolkit is free to BEVA members and can be downloaded at www.beva.org.uk.
BCF Technology has launched a competition to win a top of the range digital radiography system from its Cuattro range for 6 months.
To enter the competition, you need to record a short video (up to 2 minutes) explaining how the DR system would transform your imaging function. BCF is asking entrants to be as creative as possible as the voting will be open to the public. The company will pick a shortlist of finalists and then invite the public to vote for a winner on its Facebook page and website.
The competition is open to both small animal and equine vets, for the following systems:
Sarah O'Grady from BCF said: "Having a Cuattro DR system could make a huge difference to either a small animal or an equine practice. For a small animal vet practice that doesn't currently have a DR system, they will love the difference it makes to X-ray studies. Diagnostic images are produced in seconds and re-takes are almost non-existent. A Wireless Slate 3+ can greatly improve the ease of in-stable operations and procedures. With the removal of wires, these procedures run much smoother. You will also be surprised by the improvement in image quality."
The closing date for the competition is 30th November 2013.
To enter your video:
The winner will be required to arrange insurance for the system during the time they have the system. Full terms and conditions can be found on the BCF website.
To find out more visit the BCF website or Facebook page or call +44 (0)1506 460 023.
The new Mars Equestrian Veterinary Research Scholar Programme offers the opportunity to conduct research alongside some internationally-renowned experts in equine health and veterinary welfare while pursuing two advanced credentials: the Graduate Certificate in Animal Welfare and Behavior at Penn Vet during year one, followed by the Master of Research (MRes) program at the RVC in year two.
The RVC says the new format offers an exclusive opportunity for the candidate to refine their critical research skills and expand animal welfare knowledge while learning on location at both the RVC in England and Penn Vet’s New Bolton Center in Kennett Square, Pennsylvania, United States.
The RVC’s MRes programme gives students the chance to develop into scientists who can work well across interdisciplinary teams, tackling problems of practical relevance to veterinary and medical science. Many of the courses’ graduates go on to work in some of the world’s leading scientific research institutes, as well as within industry and government.
Professor Richard Bomphrey, Interim Vice Principal for Research at the RVC said: “I am delighted that the RVC is able to support this new transatlantic initiative for veterinary graduates following a generous donation from Mars Equestrian. It strengthens the ties between the RVC, the University of Pennsylvania and Mars Equestrian while providing an outstanding training and research opportunity. We look forward to welcoming the successful scholar and helping them to make an impact in equine research."
The Veterinary Research Scholar program is open to interested UK, US and international candidates holding a veterinary degree (DVM/VMD/BVSc or equivalent). The chosen candidate will receive an annual stipend and tuition as well as travel expenses.
The programme will commence in September 2021 in the United States before moving to the UK in October 2022 until its conclusion in September 2023.
The deadline to submit applications for consideration is 30th June 2021 or until an acceptable candidate is identified.
Applications should be sent to the Penn Vet’s Dr. Kyla Ortved atkortved@vet.upenn.edu.
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x
Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.
According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative joint disease, also known as non-infectious arthritis or osteoarthritis. The product is licensed in the UK for the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis. This is a critical treatment area since equine degenerative joint disease is estimated to cause up to one-third of all equine lameness cases1. It most commonly affects the hocks and coffin joints with the most severe effects on the high-motion knee and fetlock joints.
Esther Rawlinson MRCVS, Global Technical Services Manager for the Novartis Animal Health Companion Animal Business in the Therapeutics & Equine areas said: "Adequan Equine is a leading joint treatment for horses and is widely used by veterinarians in the equine sport industry. Adequan Equine reduces pain and lameness in horses while at the same time stimulating cartilage repair.
Adequan Equine 100mg/ml solution contains polysulphated glycosaminoglycan for intramuscular injection. It is a chondroprotective, meaning it inhibits the breakdown of cartilage in diseased joints while at the same time supporting its repair.
Adequan Equine works by blocking the destructive enzymes formed in the joint as a result of inflammation while stimulating the production of hyaluronic acid to restore the synovial fluid, and the synthesis of cartilage building compounds.
Eclipse Veterinary Software has released a new mobile addition to its equine veterinary practice management system.
Eclipse Mobile allows veterinary surgeons to access up-to-date clinical information wherever it is needed, be that on the yard, at the practice, or while making field visits.
When Eclipse Mobile is offline, all the information the vet needs is stored on the device. When next connected via 3G or Wi-Fi, any new details are sent to and from the practice - syncing notes made by the vet, adding follow-on appointments and To Do messages, services delivered and products administered to keep everyone up-to-date throughout the day.
Whilst online, client payments can be taken via debit/ credit cards within the app and detailed drug batch information recorded using the iPad/iPhone's camera as a barcode scanner, if required.
Jeanne Razzell, CEO of Eclipse said: "Many of the vets we work with have been keen to carry animal histories with them on visits, including the latest lab test results, together with recent clinical notes, and diagnostic imaging, e.g. x-rays, ultrasounds and MRI, CT or bone scans. Now, with Eclipse Mobile, every vet can have all of this information at their fingertips automatically - at every appointment; both in the consult room and on the road."
Eclipse Mobile is available for iPad, iPad mini, iPhone, Android smart phones/tablets and Microsoft Windows Surface
For more information, contact Jeanne Razzell, CEO, Eclipse Veterinary Software Limited, on +44 (0)1799 532988 or +44 (0)7515 906466. Website: www.eclipsesoftware.info
Invicta Animal Health has announced that that EquiChek test kits are now validated for use with synovial fluid, having originally been validated for whole blood only.
EquiChek is an animal-side test to assess the level of Serum Amyloid A (SAA) which is a major acute phase protein of inflammation in horses.
Invicta says that it has been shown that SAA levels in synovial fluid are not influenced by arthrocentesis*, which makes SAA an ideal biomarker to measure whilst monitoring or assessing joint function.
The company says this is the first test which is able to provide a visual semi-quantitative result within 15 minutes. The test will display 4 lines for a normal level of SAA and sequentially fewer lines depending on the severity of the inflammation.
Rob Watkins, Managing Director of Invicta, said: "EquiChek has proved to be a useful tool in the ambulatory toolkit. The validation of synovial fluid extends the use by allowing real-time monitoring of lameness and intra-articular therapies. Normally whilst medicating joints, excess synovial fluid is discarded. Now this can be utilised to assist diagnosis or to assess the response to medication."
Invicta will be at Stand A16 BEVA Congress 2013.
For further information see www.invictavet.com/ or ring 01403 791313
Dechra Veterinary Products is offering vets free Identichips® worth £100 when they order Equipalazone® Powder 100s. The European Union (EU) has now approved regulations that any equine foal born after July 1 2009 should be micro-chipped, and Defra is currently consulting with equine industry professionals about the best method of implementation. The combination of a micro-chip and horse passport provides a reliable method of identification and also a medical record. Larry King, Dechra's equine product manager said: "We want to make it easier for vets to offer clients the best method of identification and in turn, make it difficult for horses treated with veterinary medicines to enter the human food chain. "We are pleased to support the micro-chipping initiative and the Equine Passport Scheme with our Identichips offer and an owner leaflet about passports to promote responsible horse ownership. They will both help prevent important products like Equipalazone from inadvertently entering the food chain. He added: "We stand to lose up to 70 per cent of veterinary medicines if the industry and horse owners don't comply with EU legislation of horse passports and micro-chipping for every equine". The owner leaflet outlines the importance and benefits of the Equine Passport Scheme and is being inserted into every box of Equipalazone Powder 100s. Further copies are available from Dechra Veterinary Products for practices to distribute to their clients. Practices can claim their free Identichips by ordering boxes of Equipalazone Powder 100s from Rachel Horton at Dechra Veterinary Products on 01743 452 847 before August 31 2008.
VetCell is celebrating a win at Cheltenham, after 'Knowhere' won the Cotswold Chase following pioneering stem cell treatment for a serious tendon injury.
Knowhere had had a good start to his racing career as a four-year-old, winning his first two races as a novice hurdler. But after his second race in 2004 he suffered injuries to both forelimb superficial digital flexor tendons. The left fore showed low grade tendonitis while the right fore had a significant percentage of fibre rupture. As a promising racing prospect, Knowhere’s connections wanted to give him the best possible chance of recovering from his injury so they opted for stem cell therapy. He was treated by Tim Beauregard MRCVS of Summerhill Farm in Gloucestershire.
Bone marrow samples were collected from Knowhere’s sternum and were processed in VetCell's laboratory over a five week period to generate millions of stem cells. Knowhere was sedated, the tendon area was anaesthetised and the leg was then surgically clipped and disinfected. Stem cells, which had been suspended in serum obtained from the original bone marrow sample, were then injected using ultrasound guidance, into the core of the damaged area of the tendon fibres.
For the first week after the implantation Knowhere was kept in his stable to allow the cells to adapt to their new environment. Each day after this he was given walking exercise in order to stimulate the activity of the stem cells, encouraging them to differentiate into tendon cells and form into strong tendon fibres. The amount of exercise was incrementally increased, building up over a three-month period from five minutes each day to 45 minutes twice a day.
By the autumn of 2005 both of Knowhere’s tendons had healed very well and showed good fibre pattern on ultrasonography. He was re-introduced to the racetrack the following year and of the 15 or so races he has been in since, he has finished in the frame on eight occasions and has amassed some £175,000 in winnings.
Vet Tim Beauregard said: “Knowhere’s successful return to the track has been exciting and immensely satisfying to follow and he showed particularly brilliant form in the Cotswold Chase. It remains to be seen whether he will be heading for the Ryanair Chase, the Gold Cup or the Grand National but all involved will be hoping for the best.”
For more information please contact VetCell on +44 207 691 2062 or 866 764 0340, email: info@vetcell.com or visit the website at http://www.vetcell.com/
The Horserace Betting Levy Board (HBLB) has launched an online version of the Codes of Practice on equine diseases, ready for the 2011 Thoroughbred breeding season.
The website, codes.hblb.org.uk is a replica of the 2011 booklet, but with an easy to use navigator and built-in text search.
The 2011 online Codes of Practice set out minimum recommendations for the prevention and control of disease. Applying to all breeds of horse and pony, and to both natural mating and AI, the Codes cover:
The increasing mobility of horses creates a subsequent increased risk of spreading infectious disease. In recent years, most countries with active horse populations have seen incidents of these diseases, including in Britain the notifiable diseases of CEM, EIA and EVA.
Any of these diseases can have serious consequences for horse and pony breeding, compromising welfare, disrupting breeding activity and causing economic loss and distress.
Professor Willie Donachie, Chairman of the HBLB's Veterinary Advisory Committee said: "We recognise the changing ways in which vets, studs and individual breeder's access information. The new online version of the Codes is designed to reflect this and ensure that the Codes of Practice, a vital resource, are available where and when they are needed."
Two guides for equine veterinarians have just been produced by Hallmarq Veterinary Imaging covering the role of MRI in diagnosing lameness.
MRI Cases in the Standing Sedated Horse looks at fourteen cases from seven clinics in the Hallmarq user community. Compiled for Hallmarq by Dr Julien Olive DMV and complete with clinical MRI images, this 38 page booklet reviews the history, clinical examination, MRI examination, diagnosis, treatment and outcome of each case. The examples illustrate how MRI can enable a diagnosis to be made and a suitable course of treatment prescribed in difficult or ambiguous cases.
The second booklet, MRI Protocols for the Standing Sedated Horse, focuses on the procedures and terminology associated with MRI, from a brief description of the technology and the types of image that can be obtained, to a more detailed description of the methodology.
Hallmarq says that with 20 scanning centres now operating in the UK and Europe the ability now to refer selected cases for an MRI examination makes these booklets relevant to routine practice.
The booklets are available free of charge from Hallmarq for equine veterinarians and veterinary students, and they may be previewed on Hallmarq’s website.
Hallmarq Veterinary Imaging: (01483) 877812 or email info@hallmarq.net
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
BEVA is giving its members the opportunity to participate in a free practice benchmarking survey, to help them ensure their business is being run as efficiently and profitably as possible. The results of the research will be released at BEVA Congress, 7th-10th September 2011.
The Association has worked with Hazlewoods, chartered accountants and business advisors to the veterinary profession, to develop a detailed benchmarking questionnaire for equine veterinary practices, which allows businesses to compare their practice, anonymously, with other similar practices. The report should identify areas for profit improvement, including practice structure and pricing and may also highlight other potential methods of income generation.
Mark Beaney, partner at Hazlewoods and specialist advisor to the veterinary profession, said: "This is a super opportunity for equine practices to obtain helpful, free advice on how to fine-tune their business for maximum efficiency, delivery and profit. The questionnaire should take no more than half an hour to complete and in return we will provide you with a confidential individual report, with your practice data benchmarked."
Mark will present an overall report on the equine veterinary market at BEVA Congress on Saturday 10th September. All participating practices will remain anonymous. The benchmarking survey can be downloaded from the BEVA website at: http://www.beva.org.uk/news/view/59 and must be completed by 30th June 2011.
BEVA Congress runs from 7th-10th September 2011 at the Liverpool Arena Convention Centre, Liverpool. This year BEVA will be celebrating its 50th anniversary - for further information and to register visit http://www.beva.org.uk/.
Strangvac has been in development for over 25 years and Dechra says it's the first and only intramuscular vaccine to help protect against strangles.
Strangvac contains recombinant proteins CCE, Eq85 and IdeE from Streptococcus equi and has DIVA (Differentiating Infected from Vaccinated Animals) capability.
The vaccine contains no live bacteria or bacterial DNA, so will not trigger positive culture or PCR tests.
In trials the new vaccine protected more than 94% of horses1.
Dechra says it reduces the clinical signs of strangles including a high temperature, coughing, inappetence, difficulty swallowing and changes in demeanour, while also reducing the number of lymph node abscesses.
Strangvac can be given to foals from five months of age and two injections should be given at a four-week interval.
Horses at high risk of Streptococcus equi infection, such as those in livery, should be revaccinated after two months.
Based on measured antibody titres, immunological memory was found in horses following repeated vaccination six months after primary vaccination.
Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, said: “Strangvac is a ground-breaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”
https://www.dechra.co.uk/equine/vaccines
The Animal Health Trust has presented the results of a study which has identified a significant link between hind limb lameness and saddle slip, showing consistent saddle slip in some horses with hind limb lameness, even when the lameness is fairly subtle and difficult to detect.
According to the AHT, saddle slip in sports horses is a well-recognised problem that can occur for a variety of reasons, including asymmetry in the shape of the horse's back, riders sitting crookedly and ill-fitting saddles. Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust, had also observed that saddle slip may occur because of hind limb lameness. The intention of the study, therefore, was to find out more about the interrelationships between the horse, saddle and rider and to document the frequency of occurrence of saddle slip in horses with hind limb lameness compared with other horses.
The research was undertaken by Sue Dyson and Intern Line Greve and was presented at the British Equine Veterinary Association (BEVA) Congress last month. It is thought to be the first study of its kind, and was supported by the Saddle Research Trust (SRT). The SRT is a charitable organisation, aiming to facilitate research and provide support as well as advice on the influence of the saddle on the welfare and performance of horses and riders.
The study assessed 128 horses of varying size, age and type. The degree of lameness of each horse was graded; back shape and symmetry were measured and saddles assessed for symmetry and fit. Each horse was ridden by at least two riders and rider straightness plus weight were recorded. The grade of saddle slip, whether it occurred with more than one rider, and whether saddle slip was influenced by the direction of movement or the diagonal on which the rider was sitting were also noted.
The saddle consistently slipped to one side in 54% of horses with hind limb lameness, compared with 4% of horses with fore limb lameness, 0% with back pain and/or sacroiliac joint region pain and 0% of non-lame horses. Diagnostic analgesia was subsequently used to abolish the hind limb lameness and this eliminated the saddle slip in 97% of cases.
Sue said: "Our findings emphasise the need to educate owners, veterinarians, physiotherapists, trainers, riders and saddle fitters that saddle slip is frequently an indicator of lameness, not necessarily a manifestation of an ill-fitting saddle or asymmetric shape of the horse's back. Detection of saddle slip provides an opportunity for the owner, riders and trainers to detect low-grade and subclinical lameness, with important welfare consequences."
Further scientific studies are planned, with the support of the Saddle Research Trust, in order to build on these findings. To this end the SRT is currently seeking an honorary fundraiser to help secure ongoing financial support. For further information contact Anne Bondi on 07775 912202 or email annebondi@me.com.
1An investigation of the relationship between hindlimb lameness and saddle slip, L. Greve and S.J. Dyson, Centre for Equine Studies, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, CB8 7UU, UK.
Researchers at the University of Edinburgh’s Royal (Dick) School of Veterinary Studies are to start testing whether a compound of cooling chemicals, extracted from mint, can be used to treat laminitis, a condition which affects seven per cent of the British horse population.
The new project, funded by The Horse Trust and led by Professor Sue Fleetwood-Walker, builds on recent work that revealed for the first time that, there is significant nerve damage, as well as inflammation, within the hoof of laminitic horses. This explains why anti-inflammatory drugs are so ineffective in treating the pain of chronic laminitis and highlights the need for therapies to treat nerve injury-induced or ‘neuropathic’ pain in horses.
Prof Fleetwood-Walker’s team discovered in 2006 that the ‘mint’ chemicals have a pain–killing effect in laboratory studies of chronic pain. They will now investigate whether this synthetic treatment could help horses with laminitis.
Equistro has introduced Legaphyton to its range of supplements. Legaphyton has been developed to support liver function. It incorporates a new and patented complex called Siliphos®.
Siliphos® is a complex of concentrated Milk Thistle fruit extract and phospholipids, and is a source of readily available carbohydrates important for liver support.
Milk Thistle (silymarin) extract has documented virtues in liver support and is rich in flavanoligan (Silybin), while phospholipids (phosphatidylcholine) maintain healthy liver cell membrane function and repair and are crucial for essential lipoprotein transport in the liver.
“The liver is one of the most important organs and performs more often than one realises,” said Val Day, Equistro’s product manager. “Legaphyton has been introduced to give an extra boost to the horse’s liver function and help the liver fulfil its varied role.”
Equistro Legaphyton is available in 900g packs, which is sufficient for 30 days for a standard 500kg horse. Ask your Vetoquinol representative for more details or visit http://www.vetoquinol.co.uk/
.
WebLeC has launched a monthly online equine CPD service.
One hour live interactive sessions will take place every third Thursday at 7:30 pm. A single meeting costs £30 plus VAT, or savings can be made by taking out a flexible subscription that allows the user to choose any 12 meetings for the cost of 10 over a period of up to 24 months.
The next meeting is on 22nd September and is entitled: Colic Decision making: When to wake up the surgeon and what pain control to use. The presenter is Debra Archer form the University of Liverpool. Further details and registration links can be found at: http://www.ledstonequine.co.uk/weblec_lectures/colic.html
In addition, a recording of WebLeC's 6th meeting, which was held in partnership with BEVA and the VDS and dealt with the new guidelines and forms for pre-purchase examinations of horses, is now available to view free online at: www.bitly.com/weblecbevaPPE. Use the password: b3va to get access, and you will receive a CPD certificate if you fill in the registration form.
WebLeC has also been asked to host BEVA's online CPD and will be announcing further details of their meetings soon.
Fort Dodge Animal Health has announced it is working with the authorities to put measures in place to make its West Nile Virus vaccine, licensed in the United States, available to the European equine market. These measures will ensure a vaccine is readily available in the event of an outbreak in the UK.
This news comes as the Zooprophylactic Institute of Teramo, the Italian National Reference Centre for Exotic Diseases, has confirmed an outbreak of WNV among horses in stables in the northern province of Ferrara. About 20 horses are believed to have been affected.
Fort Dodge was the first company to develop and fully license a vaccine to protect horses against this potentially deadly disease. An inactivated whole virus vaccine, it was the only vaccine available in the United States at the height of the 2002 outbreak, which affected 15,000 horses. The U.S. Department of Agriculture credited the vaccine with contributing to the 70 per cent decline in U.S. equine West Nile cases since the height of the outbreak. WNV is now considered endemic in all areas of North America.
"As this latest outbreak of WNV in Italy highlights, the disease presents an increasing threat to the equestrian sector in Europe," says Helen Barnes, EMEA Equine Business Manager for Fort Dodge. "With little current natural immunity among the equine population, the consequences of a major outbreak could be devastating."
"Until now, horse owners in Europe have perhaps believed WNV is not a disease they should be concerned with but the outbreak in Ferrara came out of the blue, and at a time when a human case of WNV was also reported in the same province. This situation of both human and equine cases being reported is identical to that seen in the outbreaks in the United States. It's a stark reminder of the challenge this disease poses, particularly as environmental factors, such as global warming and heavy rains threaten to create mass breeding grounds for mosquitoes," says Barnes.
"Our experience with WNV in the United States has given us an exceptional understanding of the disease and the importance of vaccination. We now look forward to working in partnership with the European governments, the EU Commission and the veterinary community across Europe to help build understanding and knowledge of this dangerous emerging disease threat."